- Home
- INSG vs FULC Comparison
INSG vs FULC Comparison
Compare INSG & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSG
- FULC
- Stock Information
- Founded
- INSG 1996
- FULC 2015
- Country
- INSG United States
- FULC United States
- Employees
- INSG N/A
- FULC N/A
- Industry
- INSG Telecommunications Equipment
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- INSG Telecommunications
- FULC Health Care
- Exchange
- INSG Nasdaq
- FULC Nasdaq
- Market Cap
- INSG 230.9M
- FULC 221.5M
- IPO Year
- INSG 2000
- FULC 2019
- Fundamental
- Price
- INSG $12.17
- FULC $3.25
- Analyst Decision
- INSG Buy
- FULC Hold
- Analyst Count
- INSG 3
- FULC 10
- Target Price
- INSG $16.00
- FULC $7.44
- AVG Volume (30 Days)
- INSG 331.4K
- FULC 843.4K
- Earning Date
- INSG 11-12-2024
- FULC 11-13-2024
- Dividend Yield
- INSG N/A
- FULC N/A
- EPS Growth
- INSG N/A
- FULC N/A
- EPS
- INSG N/A
- FULC N/A
- Revenue
- INSG $207,478,000.00
- FULC $80,871,000.00
- Revenue This Year
- INSG $13.25
- FULC $2,821.96
- Revenue Next Year
- INSG $5.55
- FULC N/A
- P/E Ratio
- INSG N/A
- FULC N/A
- Revenue Growth
- INSG 12.59
- FULC 2987.86
- 52 Week Low
- INSG $1.60
- FULC $2.86
- 52 Week High
- INSG $20.67
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- INSG 36.44
- FULC 44.64
- Support Level
- INSG $11.90
- FULC $2.86
- Resistance Level
- INSG $13.48
- FULC $3.94
- Average True Range (ATR)
- INSG 1.38
- FULC 0.23
- MACD
- INSG -0.45
- FULC 0.02
- Stochastic Oscillator
- INSG 17.88
- FULC 36.11
About INSG Inseego Corp.
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.